Drugs / Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04486872 | Jul 2020 → May 2022 | diffuse large B-cell lymphoma | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04486872 ↗ |
| Action | Deplete | “CD19/CD20 bispecific CAR-T cell targeting multiple antigens can attack tumor cells” NCT04486872 ↗ |
| Modality | Cell therapy | “Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-cells” NCT04486872 ↗ |
| Route | Other | “Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells injection” NCT04486872 ↗ |